Fox Run Management L.L.C. Purchases Shares of 25,708 Travere Therapeutics, Inc. (NASDAQ:TVTX)

Fox Run Management L.L.C. purchased a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 25,708 shares of the company’s stock, valued at approximately $448,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. R Squared Ltd acquired a new stake in Travere Therapeutics in the fourth quarter valued at approximately $53,000. Quarry LP purchased a new stake in shares of Travere Therapeutics during the 3rd quarter valued at $105,000. Victory Capital Management Inc. acquired a new stake in shares of Travere Therapeutics in the 4th quarter worth $182,000. Baader Bank Aktiengesellschaft purchased a new position in Travere Therapeutics during the 4th quarter worth $192,000. Finally, Entropy Technologies LP acquired a new position in Travere Therapeutics during the 4th quarter valued at about $214,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Scotiabank raised their price target on Travere Therapeutics from $27.00 to $32.00 and gave the stock a “sector outperform” rating in a report on Wednesday, February 12th. Evercore ISI lifted their target price on shares of Travere Therapeutics from $33.00 to $45.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. Citigroup upped their price target on shares of Travere Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, February 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Travere Therapeutics in a report on Friday, February 21st. Finally, Canaccord Genuity Group boosted their price objective on shares of Travere Therapeutics from $22.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, February 12th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Travere Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $30.62.

Insider Activity at Travere Therapeutics

In other news, CFO Christopher R. Cline sold 5,192 shares of the firm’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $20.12, for a total transaction of $104,463.04. Following the sale, the chief financial officer now directly owns 90,038 shares in the company, valued at $1,811,564.56. This trade represents a 5.45 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Sandra Calvin sold 54,244 shares of the company’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total value of $1,356,100.00. Following the completion of the transaction, the chief accounting officer now directly owns 54,410 shares of the company’s stock, valued at $1,360,250. The trade was a 49.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 206,335 shares of company stock worth $4,453,012 in the last three months. Company insiders own 3.75% of the company’s stock.

Travere Therapeutics Stock Performance

Shares of TVTX stock opened at $21.01 on Wednesday. Travere Therapeutics, Inc. has a 52-week low of $5.12 and a 52-week high of $25.29. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The stock has a market cap of $1.86 billion, a PE ratio of -5.12 and a beta of 0.75. The business has a 50-day simple moving average of $20.64 and a 200-day simple moving average of $18.37.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.15). The company had revenue of $74.79 million during the quarter, compared to analyst estimates of $72.38 million. Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. On average, equities analysts expect that Travere Therapeutics, Inc. will post -1.4 EPS for the current year.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.